Skip to main content

Market Overview

Affimed's AFM13 In Combination With NK Cells Show Improved Tumor Recognition, Killing In Preclinical Studies

Share:
Affimed's AFM13 In Combination With NK Cells Show Improved Tumor Recognition, Killing In Preclinical Studies
  • Affimed NV (NASDAQ: AFMD) has announced the publication of in vitro and in vivo research of its lead innate cell engager (ICE), AFM13 (CD16A/CD30), combined with healthy donor-derived Natural killer (NK) cells, in Clinical Cancer Research.
  • The preclinical data demonstrated that AFM13 strongly binds to NK cells, including cytokine-activated or cord blood-derived NK (cbNK) cells, resulting in enhanced tumor recognition and antibody-dependent cellular cytotoxicity.
  • The preclinical data published supported the Investigational New Drug (IND) application for the ongoing Phase 1 study of AFM13, precomplexed with cytokine-preactivated cbNK cells followed by AFM13 monotherapy in patients with CD30-positive malignancies.
  • Results as of March demonstrated an objective response rate of 100% (overall response rate=4/4; partial response=2/4; complete response=2/4) among the first patients enrolled who were all heavily pretreated.
  • There were no observed events of cytokine release syndrome, neurotoxicity, or graft-versus-host disease.
  • Price Action: AFMD shares are trading 0.79% lower at $8.79 during the premarket session on the last check Friday.
 

Related Articles (AFMD)

View Comments and Join the Discussion!

Posted-In: Briefs cancerBiotech News Health Care Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com